Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2016

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Sorafenib

tablets 200mg dosage: 400mg bid duration: 4 weeks

PROCEDURE

laser ablation (LA)

"For LA, we use a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the tumor through four 21-gauge needles. The tips of the needles will be positioned at a distance of 15mm from each other.~When, after LA treatments, CT or MRI findings show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used."

Trial Locations (1)

80131

UOSC Epatologia - Cardarelli Hospital, Napoli

All Listed Sponsors
lead

Cardarelli Hospital

OTHER

NCT01507064 - Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter